Thus, like monoclonal antibodies against an endocytic receptor such as DEC205,17,18 XCL1-based targeting through XCR1 can mediate Ag processing and presentation, thereby leading to CD8+ T-cell responses against tumours. This evidence concerns the gene XCL1 and neoplasm.